Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial.

Cureus · 2021 · PMC8712234 · PMID 34976549

Europe PMC DOI

hedged sentence

0.0730

closest p · 1.5× alpha

0.0730

boldest claim

The sentences

marginally significantp=0.073so close (0.05 < p ≤ 0.1)

Recovery and mortality rates presented better results in the North than in the South arm: recovery rate 128% versus 67% higher at Day 14 (p=0.009) and 81% versus 51% at Day 28 (non-significantly; p=0.66), and all-cause mortality rate 83% versus 78% lower at Day 14 (marginally significant; p=0.073) and 78% versus 72% at Day 28 (p=0.004).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.